Haemonetics (NYSE:HAE) Announces Earnings Results

Haemonetics (NYSE:HAE) posted its earnings results on Thursday. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.03, Briefing.com reports. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. During the same quarter in the prior year, the business posted $0.99 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Haemonetics updated its FY25 guidance to $4.45-4.75 EPS and its FY 2025 guidance to 4.450-4.750 EPS.

Haemonetics Stock Performance

NYSE HAE traded up $0.45 during trading on Friday, hitting $86.98. 494,892 shares of the company’s stock traded hands, compared to its average volume of 545,896. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 1.15 and a beta of 0.32. Haemonetics has a 12-month low of $70.25 and a 12-month high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76. The business has a 50 day moving average of $75.42 and a 200-day moving average of $82.60.

Analysts Set New Price Targets

Several research firms have recently issued reports on HAE. Bank of America began coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price for the company. JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a research note on Tuesday, August 13th. CL King began coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 target price for the company. Citigroup reduced their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Finally, Barrington Research restated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research report on Monday, September 23rd. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $107.88.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.